Stock Financial Ratios, Dividends, Split History

SNGX / Soligenix, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.05
Volume43,800.00
Market Cap ($M)9.28
Enterprise Value ($M)2.73
Book Value ($M)4.07
Book Value / Share0.47
Price / Book2.28
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 8,740,723
Weighted Average Number Diluted Shares Outstanding Adjustment 6,144,237
Weighted Average Number Of Shares Outstanding Basic 6,144,237
Weighted Average Number Of Diluted Shares Outstanding 6,144,237
Common Stock Shares Outstanding 8,730,640
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.13
Return on Assets (ROA)-0.70
Return on Equity (ROE)-0.97
Balance Sheet (mrq) ($M)
Assets7.48
Liabilities3.41
Quick Ration/a
Current Ratio2.16
Income Statement (mra) ($M)
Revenue From Grants683,178.00
Contracts Revenue4,749,294.00
Revenues5,432,472.00
Operating Income-7.59
Net Income-7.15
Earnings Per Share Diluted-1.16
Earnings Per Share Basic-1.16
Cash Flow Statement (mra) ($M)
Cash From Operations-6.51
Cash from Investing-0.03
Cash from Financing-0.03
Identifiers and Descriptors
CUSIP834223307
Central Index Key (CIK)812796
Related CUSIPS
834223208 834223117

Split History

Stock splits are used by Soligenix, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

4h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-3)

Your Daily Pharma Scoop: Omeros' Omidria, Titan Signs Agreement, Reata Announces Top-Line Results

2018-03-23 seekingalpha
Titan has signed an agreement for commercialization rights to Probuphine in Europe and some countries in CIS, Middle East and Africa. (191-3)

CUSIP: 834223307